ROADMAP

Design, validation, selectivity, and translation-sequenced so progress stays legible before clinical claims.

Agemica sequences research through candidate design, ex vivo validation, selectivity testing, and translational planning so progress remains legible before any clinical claim is made.

Current traction map

Two tracks: therapeutic peptides and peptide vaccines.

Cancer therapies

  1. Create the platform
  2. Computational validation
  3. In-vitro validation
  4. In-vitro validation, expanded
  5. Ex-vivo validation
  6. Humanized mice / IND-enabling workWe are here
  7. Clinical trials - Phase I
  8. Clinical trials - Phase II
  9. Phase III / potential approval

Cancer vaccine

  1. Create the platform
  2. Computational validation
  3. Ex-vivo validationWe are here
  4. Humanized mice / IND-enabling work
  5. Clinical trials - Phase I
  6. Clinical trials - Phase II
  7. Phase III / potential approval
Current stage

Therapeutic track: humanized-mouse studies and IND-enabling work, following ex-vivo validation of lead combinations. Vaccine track: ex-vivo validation.

A roadmap is credible when stage gates, budgets, and outcomes are explicit.
- Roadmap principle
Next · Overview
XPRIZE milestones
Continue
 Next · Overview
Token & community
Continue